Skin Rash - Pipeline Review, Q4 2010

Description: Skin Rash - Pipeline Review, Q4 2010

Summary

Global Markets Direct's, “Skin rash Pipeline Review, Q4 2010”, provides an overview of the Skin rash therapeutic pipeline. This report provides information on the therapeutic development for Skin rash, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin rash. “Skin rash-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- A snapshot of the global therapeutic scenario for Skin rash.
- A review of the Skin rash products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Skin rash pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- A snapshot of the global therapeutic scenario for Skin rash.
- A review of the Skin rash products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Skin rash pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Skin Rash Overview
Therapeutics Development
An Overview of Pipeline Products for Skin Rash
Skin Rash Therapeutics under Development by Companies
Skin Rash Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Skin Rash Therapeutics Development
F. Hoffmann-La Roche Ltd.
Echo Therapeutics, Inc.
BioLineRx, Ltd.
Intercytex Group plc
Hana Biosciences, Inc.
Renovo Group Plc
Evolva SA
GlycoMimetics, Inc.
Universities/Institutes Involved in Skin Rash Therapeutics Development
Skin Rash Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Universities/Institutes
Januvia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Skin Rash - Featured News
Jul 08, 2010: Hana Biosciences Receives US Patent For Menadione For Prevention And Treatment Of EGFR Inhibitor Cancer Therapy-Associated Rash
Apr 12, 2010: Inhibitex Reports Results Of Interim Analysis Of Phase II Clinical Trial Of FV-100
Dec 30, 2009: Basilea Receives Complete Response Letter From FDA On Ceftobiprole For The Treatment Of Skin And Skin Structure Infections
Nov 18, 2009: Basilea's Toctino Receives Marketing Authorization In Canada
Nov 04, 2009: Cipher Pharmaceuticals Initiates A Phase III Safety Trial For CIP-ISOTRETINOIN
Sep 23, 2009: Pharming's Marketing Authorisation Application For Rhucin Validated By The European Medicines Agency
Sep 03, 2009: Pharming Submits Marketing Authorisation Application For Rhucin To The EMEA
Jul 27, 2009: Biofrontera Announces Phase II Clinical Trial Study Of BF-derm1 In Chronic Urticaria
Jun 21, 2009: BioLineRx Initiates Phase II/III Trial Of BL-5010, A Novel Formulation For The Non Surgical Removal Of Skin Lesions
Jun 04, 2009: Pharming Receives Agreement On Paediatric Investigation Plan For Rhucin From The EMEA Paediatric Committee
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Ordering:
Order Online - http://www.researchandmarkets.com/reports/1474127/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Skin Rash - Pipeline Review, Q4 2010
Web Address: http://www.researchandmarkets.com/reports/1474127/
Office Code: SCD2KDIK

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 500</td>
</tr>
<tr>
<td>Site License:</td>
<td>USD 1000</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td>USD 1500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ____________________________________________ Last Name: ________________________________________
Email Address: * ________________________________________
Job Title: ______________________________________________
Organisation: __________________________________________
Address: ______________________________________________
City: __________________________________________________
Postal / Zip Code: ______________________________________
Country: ______________________________________________
Phone Number: _________________________________________
Fax Number: ___________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World